MZE829

DRUG2 trials

Sponsors

Maze Therapeutics Inc., Maze Therapeutics

Conditions

APOL1 Kidney Disease (AKD)Proteinuric Kidney Disease

Phase 2

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

RecruitingNCT06830629

Maze TherapeuticsProteinuric Kidney Disease

Start: 2025-02-05End: 2026-09-01Target: 74Updated: 2026-07-27

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

RecruitingCTIS2024-517525-10-00

Maze Therapeutics Inc.APOL1 Kidney Disease (AKD)

Start: 2025-09-15Target: 14Updated: 2025-12-19